Redcliffe Labs acquires Pune’s Megavision Diagnostics for about Rs 40 crore

Redcliffe Labs has acquired Pune-based Megavision Diagnostics Center for approximately Rs 40 crore, adding two MRI-equipped imaging centres to its pathology network. The deal retains Megavision’s workforce and advances Redcliffe’s integrated diagnostics expansion strategy.

— Source publishedTue, 11 Aug, 2026, 10:38 IST·First seen Tue, 11 Aug, 2026, 10:40 IST·Source Entrackr · Newsletter

What happened

Redcliffe Labs acquired Pune-based Megavision Diagnostics for about Rs 40 crore, adding two MRI-equipped imaging centres to its pathology network. The deal

Key facts

  • approximately Rs 40 crore
  • 2 MRI-equipped centres
  • more than 1 crore customers served
  • over 220 cities
  • more than 80 owned laboratories
  • over 4,000 pincodes
  • more than 3,600 diagnostic tests
  • up to Rs 20 crore
  • 18 centres

Why this matters

Megavision demonstrates a tuck-in acquisition model for diagnostics players: acquire trusted local imaging assets, retain operating talent, and integrate them into a larger pathology-led platform.

What to watch

  • Additional Redcliffe acquisitions of radiology or imaging assets within the next 12 months.
  • Launch of combined pathology-and-imaging packages or unified digital booking in Pune.
  • Megavision centre utilisation, MRI appointment volumes and reported turnaround-time improvements.
  • New corporate, insurer or hospital-network contracts in Maharashtra.
  • Competitor responses from Dr Lal PathLabs, Metropolis, SRL, Tata 1mg and hospital-linked imaging chains.
  • Evidence of pricing pressure or referral-channel conflict after integration.
  • Integrate Megavision booking, reporting, home-collection and patient-data workflows into Redcliffe’s platform.
  • Bundle pathology panels with MRI, CT, ultrasound and preventive-health packages for consumers and corporate clients.
  • Seek insurer, hospital, clinician and corporate referral contracts in Pune using the combined diagnostics offering.
  • Evaluate further imaging acquisitions in high-density cities where pathology customer acquisition can feed radiology utilisation.
  • Invest in teleradiology, faster report turnaround and central quality controls across imaging sites.

Also reported by